Stockscreener 앱 받기
0.3931
0.61%
-0.0024
시간 외 거래:
.38
-0.0131
-3.33%
Genprex Inc 주식(GNPX)의 최신 뉴스
Genprex Strengthens Diabetes Focus with New License - TipRanks
Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria
Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com
Genprex explores non-viral gene therapy for diabetes - Investing.com India
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System - PR Newswire
Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria
Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com
Genprex announces advancement of its diabetes gene therapy program - TipRanks
Genprex advances diabetes gene therapy with new license - Investing.com India
Genprex Provides Update on Diabetes Gene Therapy Program - PR Newswire
Genprex faces Nasdaq delisting over stock price, equity issues - MSN
Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq
Understanding GNPX’s financial ratios: A beginner’s guide - US Post News
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - PR Newswire
Major Cancer Treatment Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer - StockTitan
Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada
Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register
Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire
Genprex Launches Pivotal Phase 2 Trial of Reqorsa Gene Therapy for Lung Cancer Treatment - StockTitan
Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World
Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SEC Form 424B5 filed by Genprex Inc. - Quantisnow
Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World
Genprex advances to phase 2 in lung cancer trial - Investing.com
Genprex's Reqorsa Advances to Phase 2 After Successful Safety Trial in Lung Cancer Treatment - StockTitan
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - The Eastern Progress Online
Genprex to Participate in 2024 BIO Europe Conference - The Eastern Progress Online
Genprex Collaborators Present Positive Preclinical Data on the U - GuruFocus.com
Genprex Collaborators to Present Positive Preclinical Data on th - GuruFocus.com
Genprex links with University of Michigan on lung cancer treatment - Yahoo Finance
Genprex secures exclusive gene therapy license for cancer By Investing.com - Investing.com Canada
Genprex secures exclusive gene therapy license for cancer - Investing.com India
Genprex Secures Global Patent Rights for Breakthrough Lung Cancer Gene Therapy | GNPX Stock News - StockTitan
Genprex faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Genprex faces Nasdaq delisting over equity shortfall - Investing.com India
U.S. Stock market top gainers: Mullen Automotive gains 92.92% while Genprex increases by 54.48% during mid day trading - Business Upturn
'Animal spirits' set to drive S&P 500 to 6,600 by mid-2025, Evercore says - Investing.com
Genprex reports promising preclinical data on cancer therapy - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - BioSpace
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Thera - GuruFocus.com
Genprex regains Nasdaq compliance with bid price rule - Investing.com India
0.27%
3.05%
자본화:
|
볼륨(24시간):